The short version of nuclear receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-10 and is reviewed periodically as new material appears.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Levobunolol (trade names AKBeta, Betagan, Vistagan, among others) is a non-selective beta blocker. It is used topically in the form of eye drops to manage ocular hypertension (high pressure in the eye) and open-angle glaucoma.
=== October === 1 October – Prime Minister Rishi Sunak announces £20m of levelling up funding to help regenerate seven Scottish towns that are described as having been overlooked. 2 October – ScotRail begins a six months trial during which peak time train fares are scrapped. 3 October – Aberdeen City Council says that reinforced autoclaved aerated concrete (RAAC) is likely to have been used in hundreds of properties in the city. 4 October – Police Scotland pays £60,000 compensation to four traffic officers told to shave off their beards before the force implemented its delayed proposals for a clean shaven policy. 5 October – Labour's Michael Shanks wins the Rutherglen and Hamilton West by-election. 6 October – Police Scotland scraps plans to recruit an extra 200 officers in January 2024 as it attempts to save costs following a projected overspend of £19m. 7 October – The Met Office issues an amber weather alert for heavy rain in Scotland, while roads and train services are disrupted by flooding. Ten people are airlifted to safety after heavy rain causes landslides on two roads in Argyll. 9 October – Bernard Cowan, a grandfather who grew up in the Glasgow area, is confirmed as one of the people killed during a series of attacks launched by Hamas against Israel on 7 October. Humza Yousaf, the First Minister of Scotland, condemns the attacks and expresses concern for his in-laws, who are "trapped" in Gaza after travelling there to visit relatives. The Scottish Medicines Consortium (SMC) approves the weight loss drug semaglutide for use by NHS Scotland.
=== Aircraft === C-4, the US Army designation of the Ford Trimotor AEG C.IV, a German World War I reconnaissance aircraft AGO C.IV, a 1917 German reconnaissance aircraft C-4 Academe, the military version of Gulfstream I twin turboprop business aircraft C-4 Argonaut, a Canadair aircraft derived from the Douglas DC-4 Cierva C.4, a 1922 Spanish experimental autogyro DFW C.IV, a 1916 German reconnaissance aircraft Flight Design C4, a four-seat light aircraft Fokker C.IV, a 1923 Dutch two-seat reconnaissance aircraft Rumpler C.IV, a 1917 German single-engine, two-seater reconnaissance biplane
We are no more boss in our own country and there is no more authority. Disorder, violence, terror, this is what affects Amsterdam and several other parts of the country. A brutally murdered lawyer, the brother of a key witness killed, rocket launcher attacks on our media outlets, grenades exploding in our streets and decapitated [sic] heads in front of our coffee shops. The Moroccan mafia has become the boss in this country. And they are getting stronger and more violent every day. Everyone in the street is fed up with the presence of Moroccans. This mafia in Amsterdam is not from Norway, it is from Morocco. Don't contradict me when I tell you that the Netherlands has a problem of Moroccans. I agree with Wilders if he says that there is a Moroccan mafia problem in the Netherlands. I also agree with him if he says that Moroccans are predominantly present in the crime statistics of the Netherlands. But I wonder what you are implying with "a problem of Moroccans in the Netherlands". The other Moroccans who are living honest lives and hear that "there is a problem of Moroccans" can be affected very deeply by this. Personally, as a liberal, as a member of this democratic society, I think that we must judge people on their individual behavior, and not on the ethnic group they belong to. Every Moroccan who wants to build a future in the Netherlands by obeying our system is in their right to do so. I have a lot of people who come to my house to complain, telling me that they see a lot of Moroccans hanging out in the alleys with bulletproof vests under their jackets.
The class of endorphins consists of three endogenous opioid peptides: α-Endorphin, β-endorphin, and γ-endorphin. The endorphins are all synthesized from the precursor protein, proopiomelanocortin (POMC), and all contain a met-enkephalin motif at their N-terminus: Tyr-Gly-Gly-Phe-Met. α-endorphin and γ-endorphin result from proteolytic cleavage of β-endorphin between the Thr(16)-Leu(17) residues and Leu(17)-Phe(18) respectively. α-endorphin has the shortest sequence, and β-endorphin has the longest sequence. α-Endorphin and γ-endorphin are primarily found in the anterior and intermediate pituitary. While β-endorphin is studied for its opioid activity, α-endorphin and γ-endorphin both lack affinity for opiate receptors and thus do not affect the body in the same way that β-endorphin does. Some studies have characterized α-endorphin activity as similar to that of psychostimulants and γ-endorphin activity to that of neuroleptics separately.
Sources: en.wikipedia.org
=== Novel experimental treatments === Though medications and behavioral treatments are effective forms for treating OUD, relapse remains a common problem. The medical community has looked to novel technologies and traditional alternative medicines for new ways to approach the issues of continued cravings and impaired executive functioning. While consensus on their efficacy has not been reached, a number of reviews have shown promising results for the use of non-invasive brain stimulation (NIBS) for reducing cravings in OUD. These results are consistent with the use of NIBS for reducing cravings of other substances. Investigations into the anecdotal evidence of psychedelics like ibogaine have also shown the possibility of decreased cravings and withdrawal symptoms. Emerging research includes the noribogaine analogue GM-3009, a next-generation neuroplastogen engineered to eliminate the cardiotoxicity of traditional ibogaine, with clinical Phase 1 trials commencing in 2026. Ibogaine is illegal in the U.S. but is unregulated in Mexico, Costa Rica, and New Zealand, where many clinics use it for addiction treatment. Research has shown a minor mortality risk due to its cardiotoxic and neurotoxic effects. In 2024 the FDA approved the NET (NeuroElectric Therapy) device, which reduces withdrawal symptoms by neurostimulation. Used for three to five days of continuous treatment, NET delivers alternating current via surface electrodes placed trans-cranially at the base of the skull on each side of the head.
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis. The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection of the urinary tract (structures that produce or carry urine), diarrhea and nausea (feeling sick).
There's always that 'what if we have to flee' mentality." Levine considered that many of the characters of Rapture were all people who were oppressed once before in their lives and now free of that oppression, have turned around and become the oppressors, a fact he felt resonated throughout human history.
=== Generic names === Oxandrolone is the generic name of the drug and its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, DCITTooltip Denominazione Comune Italiana, and JANTooltip Japanese Accepted Name, while ossandrolone is or was formerly the DCITTooltip Denominazione Comune Italiana.
=== Synthetase Domain: ATP Pyrophosphatase domain === The synthetase domain is responsible for the addition of the abstracted Nitrogen to the acceptor substrate. The ATP Pyrophosphatase domain consists of a beta sheet containing 5 parallel strands with several alpha helices on each side. The P loop is the nucleotide binding motif; residues 235-241 make up the P loop which specifically binds to pyrophosphate. The structure of this domain is what creates the specificity of this enzyme for ATP. The binding pocket forms hydrophobic interactions with the adenine ring, and the backbone of Val260 forms H bonds with multiple Nitrogens in the ring of AMP, which excludes substituents on the C2 purine ring. This creates extreme specificity for adenine and ATP binding.
Sources: en.wikipedia.org
This multidisciplinary approach allows researchers to identify vulnerable populations, characterize disparities in dementia incidence and outcomes, and evaluate interventions that may delay cognitive decline and improve quality of life for aging individuals. A defining strength of CAPAS is its emphasis on health equity and the study of historically underrepresented populations. Investigators examine racial, ethnic, geographic, and socioeconomic disparities in dementia risk, diagnosis, treatment, caregiving, and healthcare utilization, with particular attention to Hispanic, rural, and medically underserved communities throughout South Texas and the United States. By investigating the social determinants of brain health alongside biological mechanisms of aging, the Center provides critical insights into why dementia disproportionately affects certain populations and identifies opportunities to reduce inequities through targeted prevention strategies, public health initiatives, and healthcare policy. The Center also serves as an important resource for methodological innovation in population aging research. Faculty develop and apply advanced analytical approaches—including longitudinal data analysis, causal inference methods, machine learning, geospatial analysis, and health services research—to better understand the complex interactions among aging, chronic disease, cognitive decline, and social determinants of health.
α-D-mannopyranoside was the most effective for desorbing Con A from pAPM at virtually 100% after 1 hour. As a control, pAPM was used to bind Con A from a crude extract, which found the pickup of several impurities but still managed to recover 80% of Con A. This exemplifies the need for selective moieties, maltose not residing among them. Finally, the application of pAPM was tested by attempting to separate α-glucosidase from yeast extract under low temperature conditions. In conclusion, the pAPM was found to recover 68% of α-glucosidase activity tested against, maltose being the selected desorption reagent. Another interesting development for AC was involved with antibody separation using another TRP-ligand combination. Anastase-Ravion et al. attached a dextran derivative to the classic PNIPAAm to result in a poly(NIPAAm)-DD, and used this stationary phase to separate polyclonal antibodies from subcutaneous rabbit serum. From the study, the dextran derivative of choice was carboxymethyl dextran benzylamide sulfonate/sulfate, and when bound to the TRP was labeled poly(NIPAAm)-CMDBS. The LCST for the poly(NIPAAm)-CMDBS was raised from 32 °C to 33 °C. To test the success of the affinity binding, the antibodies were eluted with glycine buffer (adjusted to pH 2.6 with HCl). Promising results were obtained in 2003 in a study that merged the newer developments in affinity chromatography with microfluidic devices.
In August 2025, the United States began a military buildup in the southern Caribbean, deploying warships and military personnel. The Central Intelligence Agency (CIA) sent a team into Venezuela that began tracking Maduro's movements, using a source close to the Venezuelan president, and plans were made for the capture of Maduro months in advance. The Delta Force and other participants in the operation erected a mockup of the safe house in which Maduro was believed to be hiding, described by Trump as a "very highly guarded ... fortress". In September, the United States Southern Command began conducting military strikes on vessels in the Caribbean Sea, alleging some were trafficking drugs on behalf of Venezuela. In November 2025, Venezuelan opposition leader María Corina Machado promised to open Venezuela's oil and gas reserves during a business meeting in Miami attended by Trump, and the Trump administration engaged in secret talks with Maduro's government about its oil reserves. In December 2025, this escalated to include seizures of sanctioned oil tankers carrying Venezuelan crude. These seizures formed part of the broader blockade on sanctioned oil preceding the January 2026 operation. The US also launched covert operations in Venezuela under the directive of the CIA in late December. On 2 January 2026, Trump announced that the US military would conduct strikes inside Venezuela. In the weeks preceding the operation, Trinidad and Tobago signed an agreement with the US to allow US military access to its airports.
The first MP, installed at Yale in 1963, operated consistently at 10–11 megavolts; a later installation at Strasbourg reached 18. At these energies, electron stripping becomes highly efficient. A uranium ion passing through the terminal can lose more than 20 electrons, enabling heavy-ion fusion experiments impossible with earlier machines. Advances in gamma-ray spectroscopy combined with MP tandems enabled precision measurements of nuclear structure. HVEC manufactured 10 MP units between 1965 and 1973 for institutions including the University of Minnesota, Chalk River, and the Max Planck Institute in Heidelberg. The XTU ("Holy Roman Emperor") was designed for superheavy element synthesis. Theoretical models predicted an "island of stability" beyond element 110 where nuclei would resist rapid decay. The XTU's 20-megavolt rating would accelerate uranium ions to nearly one billion electron volts—enough to overcome Coulomb barriers in heavy-element fusion. Two prototypes operated solely on a test basis at Burlington before the project was cancelled. One later sold to Italy's national laboratory at Legnaro in 1979.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.